The initiation of the NDA submission for apraglutide is a significant step for Ironwood Pharmaceuticals, potentially leading to future revenue if approved. However, the announcement of job cuts may indicate cost-cutting measures or restructuring, which can be perceived negatively by investors. This combination of news has resulted in a short-term decline in the stock price.